explore -WSS

explore

author：Wikipedia 2025-10-01 14:59:51 - browse：6

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： David Liu startup to focus on CRISPR delivery

WSS

People with substance use disorder deserve online privacy

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

'A game

Diversify hospital leadership teams to protect BIPOC patient health

UCSF medical school apologizes for unethical prisoner experiments

Fed up with FDA, ALS advocates consider a take

hotspot

explore

hotspot

Drug repurposing or repositioning? The language matters

A clever new way to fix Medicaid and graduate medical education

The cancer drug shortage isn’t new — and neither are the solutions

Removing probiotics from the NICU could threaten preemies' health

How one medical school became remarkably diverse

The Sacklers, horror, and ‘The Fall of the House of Usher’

Apple is now the first public company to be valued at $3 trillion

FDA approves Recor Medical high blood pressure device

Trump demands the U.S. pay no more for drugs than other countries … again

Transgender sports debate: Physicians say bans are health issue

Wikipedia

David Liu startup to focus on CRISPR delivery

The struggle to figure out which patients 'deserve' Wegovy

A clever new way to fix Medicaid and graduate medical education

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Medicare to pay more for cardiac rehab in hospital outpatient clinics

FDA approves Recor Medical high blood pressure device

Wikipedia

focus

leisure time

focus